Physicochemical properties of liposomal modifiers that shift macrophage phenotype
- 1 October 2017
- journal article
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 79, 237-244
Abstract
No abstract availableKeywords
Funding Information
- National Science Foundation (CBET−1227867)
- Roy J. Carver Charitable Trust (13-4265)
- NSF ARI-R2 (CMMI-0963224)
This publication has 57 references indexed in Scilit:
- Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of diseaseExpert Review of Molecular Diagnostics, 2013
- Liposome: classification, preparation, and applicationsDiscover Nano, 2013
- Liposomal drug delivery systems: From concept to clinical applicationsAdvanced Drug Delivery Reviews, 2013
- Doxil® — The first FDA-approved nano-drug: Lessons learnedJournal of Controlled Release, 2012
- Targeted Liposomal Drug Delivery to Monocytes and MacrophagesJournal of Drug Delivery, 2010
- Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future ProspectsCurrent Pharmaceutical Design, 2010
- Investigation into the Role of Tumor-Associated Macrophages in the Antitumor Activity of DoxilPharmaceutical Research, 2008
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Delivery of Liposomal Doxorubicin (Doxil) in a Breast Cancer Tumor Model: Investigation of Potential Enhancement by Pulsed-High Intensity Focused Ultrasound ExposureAcademic Radiology, 2006
- Diffusion of univalent ions across the lamellae of swollen phospholipidsJournal of Molecular Biology, 1965